Market Mover: Brooklyn ImmunoTherapeutics (BTX) Climbs at Midday August 5

Equities Staff  |

Brooklyn ImmunoTherapeutics Inc (NYSE: BTX) shares have risen 9.90%, or $0.0495 per share, as on 11:47:42 est today. Opening the day at $0.53, 321,504 shares of Brooklyn ImmunoTherapeutics exchanged hands and the stock has ranged between $0.57 and $0.52.  

This year the company has moved YTD 87.53%.

Brooklyn ImmunoTherapeutics expects its next earnings on 2022-08-15.

For technical charts, analysis, and more on Brooklyn ImmunoTherapeutics visit the company profile.

About Brooklyn ImmunoTherapeutics Inc

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

To get more information on Brooklyn ImmunoTherapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Brooklyn ImmunoTherapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

These Stocks are Sending a Signal (like Amazon in 2008)
It Isn’t a Recession Until This Group of Economists Says So
What You Should Know About Europe's Energy Wars
Meatless Meats and Smokeless Smokes
Mixed Wireless Recovery at AT&T, Verizon, T-Mobile: Jeff Kagan



Market Movers

Sponsored Financial Content